“At Seer, we are passionate about empowering more researchers to access deep, unbiased proteomics so that we can really begin to fundamentally understand biology in a functional and dynamic way,” said
Panome Bio’s Next-Generation Metabolomics technology was developed by Chief Scientific Officer, Dr.
The Proteograph XT Assay in combination with Seer’s Proteograph Product Suite, enables deep, unbiased proteomics studies with unprecedented sight, scope, speed, and scale. Seer’s proprietary engineered nanoparticles enhance the detection of novel variants and biomarkers, enabling researchers to gain direct sightlines into the proteome at the peptide level, with a depth of greater than 6,000 proteins and more than 55,000 peptide IDs in complex samples such as plasma. The Proteograph XT solution is species and sample agnostic, adding flexibility and scope to any study, supporting samples from biofluids to skeletal muscle, and studies leveraging from small to large model organisms. With a fully automated workflow and minimal hands-on time, researchers can now conduct unbiased proteomics studies of significance with hundreds or thousands of samples, quickly and efficiently.
More information on the Seer COE Program can be found at https://seer.bio/company/service-providers-of-seer-technology/.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite with the new Proteograph XT Assay is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
About Panome Bio
Panome Bio is a discovery services contract research organization that helps its clients profile the metabolome and proteome to further their research in disease and drug development. Panome Bio provides a comprehensive workflow including experimental design, sample preparation and analysis, and data processing. For more information, please visit www.panomebio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the delivery of unprecedented depth and scale in complex biological samples, the integration of data and analysis protocols, understanding health and disease, acceleration of insights into biology, the detection of novel variants and biomarkers, the depth of protein and peptide identification, and the
Media Inquiries:
pr@seer.bio
alexandra.harrison@panomebio.com
Investor Inquiries:
Carrie Mendivil
investor@seer.bio
Source:
2023 GlobeNewswire, Inc., source